We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know
Read MoreHide Full Article
In the latest close session, Pfizer (PFE - Free Report) was down 2.75% at $24.04. The stock trailed the S&P 500, which registered a daily loss of 0.1%. On the other hand, the Dow registered a gain of 0.35%, and the technology-centric Nasdaq decreased by 0.43%.
The drugmaker's stock has dropped by 4.37% in the past month, falling short of the Medical sector's gain of 1.97% and the S&P 500's loss of 1.34%.
Market participants will be closely following the financial results of Pfizer in its upcoming release. The company plans to announce its earnings on August 4, 2026. In that report, analysts expect Pfizer to post earnings of $0.68 per share. This would mark a year-over-year decline of 12.82%. Simultaneously, our latest consensus estimate expects the revenue to be $14.4 billion, showing a 1.71% drop compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $2.99 per share and revenue of $61.64 billion, which would represent changes of -7.14% and -1.49%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Pfizer. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Pfizer is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that Pfizer has a Forward P/E ratio of 8.28 right now. Its industry sports an average Forward P/E of 15.31, so one might conclude that Pfizer is trading at a discount comparatively.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 94, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest close session, Pfizer (PFE - Free Report) was down 2.75% at $24.04. The stock trailed the S&P 500, which registered a daily loss of 0.1%. On the other hand, the Dow registered a gain of 0.35%, and the technology-centric Nasdaq decreased by 0.43%.
The drugmaker's stock has dropped by 4.37% in the past month, falling short of the Medical sector's gain of 1.97% and the S&P 500's loss of 1.34%.
Market participants will be closely following the financial results of Pfizer in its upcoming release. The company plans to announce its earnings on August 4, 2026. In that report, analysts expect Pfizer to post earnings of $0.68 per share. This would mark a year-over-year decline of 12.82%. Simultaneously, our latest consensus estimate expects the revenue to be $14.4 billion, showing a 1.71% drop compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $2.99 per share and revenue of $61.64 billion, which would represent changes of -7.14% and -1.49%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Pfizer. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Pfizer is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that Pfizer has a Forward P/E ratio of 8.28 right now. Its industry sports an average Forward P/E of 15.31, so one might conclude that Pfizer is trading at a discount comparatively.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 94, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.